MUC1 is an antigen that is overexpressed on the cell surface of many human breast adenocarcinomas and other types of cancer. The cancer immunity cycle has seven steps, starting with release of cancer cell antigen and following with cancer antigen presentation. Priming, activation and trafficking of T cells to tumors are the next steps and the infiltration of T cells into tumors, the recognition of cancer cells by T cells and killing of cancer cells are the final steps. We have tested a synthetic peptide for the MUC1 antigen and generated dendritic cells (DCs) that were pulsed with the specific peptide. Mature DCs were used to activate naive T cells to differentiate into antigen-specific CTLs. CTLs were tested for proliferation, cytokine release (IFNγ), activation markers and cytotoxicity against human breast adenocarcinoma cell lines. The cytotoxic effect of those CTLs was higher against MCF7 human cell line than against MDA-MB-231 human cell line.
system has opened up new avenues for reducing death rates. Breast cancer was not originally thought to be immunogenic, but immunotherapy has had encouraging results in the past few years. Cancer immunotherapy is triggering patient's immune system to attack and kill tumor cells. Moreover, treatment can be used as an important addition to conventional therapies [2] . Adoptive immunotherapy is the ex vivo activation and expansion of tumor-specific immune cells and infusion of those cells into cancer patients. Cytotoxic T lymphocytes generated from naïve CD8 T cells seem to have potent cytotoxic activity and can be used in adoptive immunotherapy [3] [4] . Molecular identification of human cancer antigens and in vitro techniques, which are allowing generation of large numbers of dendritic cells (DCs) that are presenting cancer antigens to T cells, have given new prospects at the concept of cancer immunotherapy [5] .
Immature DCs have high phagocytic activity and they are able to capture antigens. Delivery of antigens to DCs can be employed by several systems including viral vectors, defined peptides and undefined peptides, RNA from tumor cells, whole tumor lysates and fusion with tumor cells. Immature DCs can capture killed tumor cells and present their antigens. Antigen-presenting mature DCs are able to activate antigen-specific cytotoxic T lymphocytes [6] . Cytotoxic T lymphocyte (CTL), also known as CD8 + T cell, is a type of T lymphocyte that is important for immune defence against potentially threatening pathogens and cancer cells [7] . Tumor fitness is the prediction whether a cancer cell will be attacked by immune cells (T cells). Strong immune response against the tumor means that there is low tumor fitness [8] . High tumor fitness is related with loss of function of immune cells and an increase in the amount of checkpoint inhibitors such as cytotoxic T lymphocyte antigen 4 (CTLA4), programmed cell death protein 1 (PD1) and lymphocyte activation gene 3 protein (LAG3) that are markers of T cell exhaustion [9] [10] [11] .
It is critical to identify the most potent stage of human DCs for designing successful DC-based immunotherapy protocol. Immature DCs are mainly located in peripheral tissues where they capture antigens. The stimuli is necessary to switch DCs to immunostimulatory mode. The maturation process is associated with changes in phenotype and function, with upregulation of adhesion molecules and expression of chemokine receptors [12] . Mature DCs are potent in priming naive CD8 T cells and in expanding memory CD8 T cells. Mature DCs can be used as immunotherapy adjuvants for priming and efficient differentiation of naive CD8 T cells into cytotoxic T cells [13] .
The epithelial mucin MUC1 is a highly glycosylated type I transmembrane glycoprotein that is overexpressed on the cell surface of many human breast and ovarian adenocarcinomas as well as on some multiple myelomas and B cell lymphomas, but not on the surface of normal cells. Its expression is associated with predominantly, but not exclusively, epithelial tumor cells. Abnormal expression of MUC1 has been associated with metastatic process of tumor cells and the expression is higher in progressive and metastatic tumor cells than in primary tumor cells. It is recognized as an attractive target for immunotherapeu- [15] . MUC1 continues to arouse interest as a therapeutic target and there is an increase in MUC1-based clinical trials initiated in 2017 [16] . MUC1 79-87 TLAPATEPA is a non-variable number tandem repeat region MUC1-derived HLA-A* 02:01-restricted epitope that elicits peptide specific cytotoxic T lymphocyte (CTL) immunity. It can be used as component of peptide-based vaccines and can be used in research of anti-MUC1 CTL responses of patients with MUC1 positive tumors [17] .
The present study aimed to extend the possibility of using MUC1-derived T cell epitopes to induce immunotherapeutic approaches. To prove the presentation of T cell epitopes by the cancer cells, induction of MUC1-specific CTLs was performed in vitro using peptide-pulsed DCs as antigen-presenting cells. Hence, evaluation of their functional status in terms of proliferation, cytotoxicity and cytokine release against two human breast adenocarcinoma cell lines was done.
Materials and Methods

Cell Culture
Cancer cell lines were purchased from ECACC (European Collection of Authen- 
Synthetic Peptide
HLA-A* 02:01-binding peptide MUC1 79-87 TLAPATEPA was used for in vitro stimulation of T cells and purchased from GenScript (Leiden, Netherlands). It was >90% pure as indicated by analytical high-performance liquid chromatography.
DCs Generation from Monocytes
In order to generate DCs, monocytes were isolated by peripheral blood mono- 
Generation of Antigen-Specific CTL
Peripheral blood mononuclear cells (PBMCs) of healthy donors (HD) (females, 25 -30 years old) were isolated with Ficoll-seperation (Biocoll separating solution-Catalog#1077, Biochrom, Berlin, Germany). Monocytes could be separated from lymphocytes given their ability to adhere to the surface of the flask. Non-adherent T cells were collected and added in co-culture with mature DCs in a 12-well plate in OpTmizer TM CTS TM T-Cell Expansion medium Catalog#A1048501 (ThermoFischer Scientific, Darmstadt, Germany) with the addition of IL-2 (10 ng/ml) Catalog#11340023 (ImmunoTools, Friesoythe, Germany). The ration of T cells to DCs was 30:1. At day 7 of co-culture, thawing of an aliquot of mature DCs for stimulation of T cells was done with the addition of IL-7 (5 ng/ml) Cat-alog#11340072 (ImmunoTools, Friesoythe, Germany) and IL-2 (10 ng/ml). At day 14 of co-culture, thawing of the last aliquot of mature DCs and stimulation of T cells in the same way of first and second stimulation was done with the addition of IL-7 (5 ng/ml) and IL-2 (10 ng/ml). On day 21 of co-culture, CD8+ T cells were isolated from co-culture by positive selection with magnetic beads Catalog#39-CD8-250 (Gentaur, Kampenhout, Belgium) and the cells were ready to be assessed for CTL activity [18] .
Immunophenotyping
Flow cytometric analysis of monocyte derived DCs was performed by direct immunofluorescence of cell surface antigens using antibodies against CD11c conjugated with APC Catalog#21487116 ( 
T Cell Proliferation
T cell proliferation was assessed with CellTrace TM CFSE Cell Proliferation Kit Catalog#C34554 (ThermoFischer Scientific, Darmstadt, Germany) according to the manufacturer's suggestions. After five days of co-culture with DCs, live T cells were analysed for Carboxyfluorescein Diacetate Succinimidyl Ester (CFSE) dilution by flow cytometry.
Cytokine Production
On days 6 and 12 of co-culture with mature DCs, supernatants were harvested and frozen at −80˚C until used. Levels of cytokine IFN-γ were determined using an ELISA kit Catalog#31673539 (ImmunoTools, Friesoythe, Germany) according to manufacturer's suggestions. Absorbance at 450 nm with reference wavelength at 605 nm was taken and the optical density was compared with the optical density of unstimulated T cells. . 50 μl of substrate were added to the corresponding wells and microplate was left to incubate for 30 minutes at room temperature in the dark. Absorbance was measured at 490 nm using an ELISA reader and reference wavelength was at 605 nm.
LDH Cytotoxicity Detection Assay
Statistical Analysis
One sample t-test was used to determine differences in the mean. P values < 0.05 were considered to indicate a statistically significant difference.
Ethics Approval
All procedures were conducted according to the standards of Safety, Bioethics and Validation. The study was reviewed and approved by Bioethical Committee of the Research Genetic Cancer Centre Group. Each healthy donor (HD) provided informed consent in writing for the use of their sample in the present study. The healthy donors (HD) retained the right to withdraw their sample until the date when the sample was received at the laboratory and tested.
Results
DC Generation
The generation of immature DCs and the progress of the development of mature DCs was reviewed by phase-contrast inverted microscopy (Figure 1 ). At the beginning of the culture, monocytes were spherical and adherent to the surface of the flask. At day 5, immature DCs were found forming clusters suspending in culture medium. Upon maturation, DCs were transformed into large irregular cells with cytoplasmic projections.
Cell Surface Activation Markers Indicating Mature Phenotype of DCs
Flow cytometric analysis of DCs revealed significant differences in the expression of surface molecules (Figure 2 ). DCs were gated according to forward (FSC) and side (SSC) scatter profile. Immature DCs showed a substantially enhanced expression of CD11c, low expression of CD80, CD86 and very low expression of CD83. On the other hand, mature DCs showed high expression of CD86 and CD83 and were positive for CD80 (Table 1 ).
Stimulation of T Cells by MUC1-Pulsed DCs
The ability of mature DCs to stimulate T cells proliferation was determined by 
Cytokine IFN-γ Release by Stimulated T Cells
T cells were in culture alone, in co-culture with MUC1-pulsed DCs and in Journal of Cancer Therapy co-culture with DCs that had not been pulsed with any peptide. Supernatants from all the above cultures harvested and analyzed with ELISA for IFNγ release.
When comparing the release of IFNγ between T cells alone and T cells that had
been in co-cultivation with MUC1-pulsed DCs, there was a statistically significant higher expression of IFNγ in both 6 and 12 days, in the supernatants of
MUC1 primed T cells. A statistically significant difference was also observed between the culture of T cells with MUC1-pulsed DCs and T cells cultures with
DCs that had not been pulsed in the samples harvested at 12 days. IFNγ release was higher in the co-cultivation with MUC1-pulsed DCs (Figure 4 ).
Cell Surface Markers Displaying Activation of Cytotoxic T Lymphocytes
The activation of cytotoxic T lymphocytes was assessed by flow cytometry against four markers ( Figure 5 ). The expression of CD11a was much higher on stimulated cells than on unstimulated T cells, reaching 72.04%, while on unstimulated the expression was 38.46%. For the rest of the markers, there was a slightly higher value in the expression on the stimulated T cells than on the cells that had not been stimulated. Stimulated T cells had a very low expression of CD25-0.55%, CD69-2.25% and CD62L-1.17%, while the unstimulated T cells exhibited even lower expression of CD25-0.29%, CD69-2.19% and CD62L-0.69%.
Detection of MUC1-Specific T Cell Cytotoxic Activity
We assessed the cytotoxic activity of antigen-specific CTLs with LDH Cytotoxic- Figure 6 ).
Discussion
The present study was designed to identify cytotoxic T lymphocyte generation from MUC1 antigen-pulsed dendritic cells and the cytotoxic activity of those [3] . One promising area in cancer immunotherapy is T cell co-culture with antigen-pulsed DCs. One mature DC is able to efficiently activate approximately 100 T cells, whereupon they can trigger an immune response. In vitro co-culturing of T cells and DCs could be used to avoid the negative influence of tumor growth products that are depressing the functional activity of mature antigen-pulsed DCs administered to the patient [20] .
Mature DCs are significantly better at CTL induction due to higher expression of MHC and costimulatory molecules than CTL induction by immature DCs.
The presentation of tumor antigens by immature DCs may lead to tolerance induction in the absence of proper co-stimulation. In peripheral lymphoid organs immature DCs are not able to elicit CTL responses. Mature DCs express high levels of co-stimulatory molecules, resulting in priming of antigen-specific CTLs, if there is sufficient co-administration with antigens to stimulate DCs activation [21] [22] . Mature DCs were able to induce the full complement of T cell activation, IFNγ production, T cell proliferation and development of cytotoxic T cells [23] . Naïve CD8 T cells do not produce large amounts of IFN-γ, but differentiation in CTLs is triggering the production of higher levels of the cytokine [24] [25] . In the present study, we observed that activated T cells with MUC1-pulsed DCs produced higher levels of IFNγ cytokine than naive CD8 T cells. This was the first sign that we could have achieved successful differentiation of naive CD8 T cells in CTLs. Moreover, IFNγ production was higher in T cells that were stimulated with MUC1-pulsed DCs than those that were stimulated with mature DCs that had not been pulsed with any peptide. It might be a result suggesting the specificity of differentiated CTLs against MUC1 antigen.
Loaded DCs with tumor antigens can induce CD8 T cell proliferation. It was observed that DCs loaded with MUC1 peptide induced CD8 T cell proliferation and naive CD8 T cells that were used as control had not undergone up to any divisions. Co-cultivation of CD8 T cells with mature DCs and the addition of IL-2 is necessary to induce maximal proliferation of purified CD8 T cells [26] . Naive CD4 T cells had no signs of proliferation and activated CD4 T cells showed lower levels of proliferation than activated CD8 T cells. CD8 T cells become responsive to low doses of IL-2 quicker than CD4 T cells [27] .
CD11a plays a critical role in T cell infiltration and activation. Change in the frequency of CD11a expression can be used to track antigen-specific CD4 and CD8 T cell responses followed T cell-targeted vaccination. It is crucial for the optimal expansion of antigen-specific CD4 and CD8 T cells [28] . CD25 plays a role in the proliferation and survival of activated T lymphocytes. It is expressed at low levels in resting lymphocytes and it is increased upon activation in a time-dependent manner, remaining elevated until 24 hours and declining thereafter [29] . In the present study, the analysis has been performed many days after the activation signal and it was clear that CD25 expression was at very low levels. CD69 is another early marker of lymphocyte activation due to its rapid Journal of Cancer Therapy appearance on the surface of the plasma after stimulation [30] . Similarly to CD25, the expression of CD69 by the stimulated T cells with MUC1-pulsed DCs was very low. CD62L is shed from the cell membrane following T cell activation.
Naive CD8 T cells are showing higher expression of CD62L, but the expression
is decreased when T cell differentiate into effector phase [31] . Higher CD62L expression is correlated with central memory T cell phenotype. The slight increase that we observed in the expression of CD62L by stimulated T cells might be the result of the extent of cell division that might be associated with the extent of memory formation.
After stimulation of cytotoxic T cells with antigen-pulsed DCs, LDH cytotoxicity test was performed to study the cytotoxic activity of MUC1 antigen-specific CTLs against human breast adenocarcinoma cell lines. Chromium ( 51 Cr) release assay has been widely used for detecting the cytolytic activity of CTLs. Despite the sensitivity and efficiency of the assay, this method has a great drawback, the use of radioactive materials, which is related with environmental safety concerns and inconvenience to handle [32] . LDH cytotoxicity detection assay is a non-radioactive alternative to chromium release assay and is based on detection of cytosolic enzyme that is released in culture medium from the cytosol of damaged cells. It is a colorimetric assay for quantification of cell lysis and death [33] . Further studies are needed to determine the potential therapeutic value of cytotoxic T lymphocytes that are generated by antigen-pulsed DCs. In vitro results have to be compared with in vivo results for safety, efficacy and validation that there are no side effects following that specific immunotherapy is crucial. Identification of shared cancer antigens that potentially might be presented by DCs and could generate CTLs with high cytotoxicity activity, is very important for the standardization of the protocols and the development of a valid therapeutic proposal.
Conclusion
Pulsing of DCs with antigenic epitopes and the use of those DCs in activation of naïve CD8 T cells to become cytotoxic T lymphocytes may be considered a novel approach to adoptive immunotherapy.
